Effects of Body Composition on Vascular Health in Females With a Healthy Body Weight
Ball State University · NCT06818500
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–50 · Women only
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 30
- US sites recruiting
- 1
- Study start
- September 1, 2024
- Record last updated
- April 24, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Most of the time, body weight is evaluated by looking at the ratio of your weight to your height. This measurement is called body mass index or BMI. However, BMI does not account for what your body is actually made up of (e.g., body fat versus muscle), which may be more important for determining cardiovascular disease risk. The investigators aim to understand vascular health in females with a "healthy" BMI with differing amounts of body fat and muscle mass. We will have participants come to the lab for two different study visits. At one visit, participants will eat a meal high in fat, and at the other visit, participants will undergo a stress task.
Being studied: high-fat meal; Stress
Conditions: Normal-weight Obesity; BMI; Stress
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- You are 18-50 years old
- Your biological sex is female
- BMI is in "normal" category (18.5-24.9 kg/m2) - this BMI requirement is due to our research aims
- You are not pregnant or expecting to become pregnant
- You are not postmenopausal
- You have not been diagnosed with a cardiometabolic condition (e.g., cardiovascular disease, type 2 diabetes)
- You have not been diagnosed with a chronic inflammatory condition (e.g., rheumatoid arthritis, inflammatory bowel disease).
- You do not regularly take anti-inflammatory drugs (more than 2x week) or are able to temporarily suspend use of anti-inflammatory drugs.
- You do not use lipid-lowering drugs (e.g., statins), glucose-lowering drugs (e.g., metformin) tobacco products, or any illicit drugs
- You do not have a pacemaker.
- You do not have dietary restrictions prohibiting you from eating the provided meal (e.g., vegan/vegetarian diets, gluten-free diet, relevant food allergies).
- You are able to stay in the supine position in the dark for at least 10 minutes
Exclusion Criteria
- You are not 18-50 years old
- Your biological sex is not female
- Your BMI is not in the "normal" category (18.5-24.9 kg/m2) - this BMI requirement is due to our research aims
- You are pregnant or expecting to become pregnant (females only)
- You are postmenopausal
- You have been diagnosed with a cardiometabolic condition (e.g., cardiovascular disease, type 2 diabetes)
- You have been diagnosed with a chronic inflammatory condition (e.g., rheumatoid arthritis, inflammatory bowel disease).
- You regularly take anti-inflammatory drugs (more than 2x week) or are unable to temporarily suspend use of anti-inflammatory drugs.
- You use lipid-lowering drugs (e.g., statins), glucose-lowering drugs (e.g., metformin) tobacco products, or any illicit drugs
- You have a pacemaker.
- You do have dietary restrictions prohibiting you from eating the provided meal (e.g., vegan/vegetarian diets, gluten-free diet, relevant food allergies).
- You are unable to stay in the supine position in the dark for at least 10 minutes
Recruiting US locations
Ball State University- Nutrition Assessment Lab
Muncie, IN 47303
Site contact: Bryant H Keirns, PhD · 7652858356 · bryant.keirns@bsu.edu
Study contacts (from the official record)
- Bryant H Keirns, PhD · 7652858356 · bryant.keirns@bsu.edu
Similar studies in Indiana
All weight loss studies in Indiana →- RecruitingPhase 3
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
Pfizer
- Location
- Evansville, IN + 29 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
AstraZeneca
- Location
- Indianapolis, IN + 43 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
Eli Lilly and Company
- Location
- Brownsburg, IN + 24 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Amgen
- Location
- Munster, IN + 136 other US sites
- Eligibility basics
- Ages 45–99